These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Preskorn SH Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Baumann P Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Sánchez C; Hyttel J Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421 [TBL] [Abstract][Full Text] [Related]
5. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Carrasco JL; Sandner C Int J Clin Pract; 2005 Dec; 59(12):1428-34. PubMed ID: 16351675 [TBL] [Abstract][Full Text] [Related]
8. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. Foster RH; Goa KL CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224 [TBL] [Abstract][Full Text] [Related]
10. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Baumann P Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():5-11. PubMed ID: 8732438 [TBL] [Abstract][Full Text] [Related]
11. The pharmacogenetics of the selective serotonin reuptake inhibitors. Brøsen K Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052 [TBL] [Abstract][Full Text] [Related]
12. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Caccia S Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301 [TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Baumann P; Rochat B Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807 [TBL] [Abstract][Full Text] [Related]
14. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Sproule BA; Naranjo CA; Brenmer KE; Hassan PC Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993 [TBL] [Abstract][Full Text] [Related]
15. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Ball SE; Ahern D; Scatina J; Kao J Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. Gury C; Cousin F Encephale; 1999; 25(5):470-6. PubMed ID: 10598311 [TBL] [Abstract][Full Text] [Related]
18. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Hemeryck A; Belpaire FM Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575 [TBL] [Abstract][Full Text] [Related]
19. [Fluoxetine: an update of its use in major depressive disorder in adults]. Gourion D; Perrin E; Quintin P Encephale; 2004; 30(4):392-9. PubMed ID: 15597466 [TBL] [Abstract][Full Text] [Related]